Enzon Pharmaceuticals, Inc. is a pharmaceutical company. Its headquarters is in Piscataway, New Jersey. The company is a publicly traded company on NASDAQ under the symbol "ENZN". It's also doing marketing works in Asia areas such as China. In 2012, the company orally presented in Nanjing, China about the symposium of its drug delivery systems, which help improve therapeutic molecules' pharmaceutical properties.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ENZN | ENZON PHARMACEUTICALS, INC. | 2025-10-28 10:42:25 | 0.07 | 0.01 | 13.33 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENZN | 0000727510 | ENZON PHARMACEUTICALS, INC. | US2939041081 | 529900VN48L8QCMVPV36 | 222372868 | OTC | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 20 COMMERCE DRIVE, SUITE 135 | CRANFORD | NJ | 07016 | UNITED STATES | US | 732-980-4500 | 20 COMMERCE DRIVE, SUITE 135, CRANFORD, NJ, 07016 | 20 COMMERCE DRIVE, SUITE 135, CRANFORD, NJ, 07016 | ENZON PHARMACEUTICALS INC | — | 1981 | George W. Hebard III, M.B.A. | — | http://enzon.com/ | 6,814,434 | 74,214,603 | 74,214,603 | Enzon Pharmaceuticals, Inc. is a pharmaceutical company. Its headquarters is in Piscataway, New Jersey. The company is a publicly traded company on NASDAQ under the symbol "ENZN". It's also doing marketing works in Asia areas such as China. In 2012, the company orally presented in Nanjing, China about the symposium of its drug delivery systems, which help improve therapeutic molecules' pharmaceutical properties. | 2025-10-23 17:23:25 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 6,814,434 | -777,069 | -10.236 | 74,214,603 | 0 | 0 |
| 2023 | 7,591,503 | -4,175,327 | -35.4839 | 74,214,603 | 0 | 0 |
| 2022 | 11,766,830 | -13,285,131 | -53.0303 | 74,214,603 | 0 | 0 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Richard L. Feinstein | Chief Financial Officer, Secretary, Chief Executive Officer | 2023 | 0 | 15,000 | 0 | — | 209,068 | 224,068 |
| Richard L. Feinstein | Chief Financial Officer, Secretary, Chief Executive Officer | 2022 | 0 | 10,000 | 0 | — | 199,452 | 209,452 |
| Richard L. Feinstein | Chief Financial Officer, Vice President | 2016 | 0 | — | 0 | 0 | 159,506 | 159,506 |
| Andrew Rackear | Secretary, Chief Executive Officer | 2016 | 0 | — | 0 | 0 | 139,157 | 139,157 |
| George W. Hebard | Secretary, Chief Operating Officer, Principal Executive Officer | 2016 | 0 | — | 0 | 0 | 13,635 | 13,635 |
| Fiscal Year | Employee Count |
|---|---|
| 2012 | 43 |
| 2011 | 72 |
| 2010 | 126 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 26,000 | — | 26,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | — | — | — |
| General And Administrative Expenses | — | — | — |
| Operating Expenses | 1,353,000 | 1,044,000 | 1,058,000 |
| Operating Income | -1,327,000 | -1,044,000 | -1,032,000 |
| Net Income | 778,000 | 1,373,000 | -186,000 |
| Earnings Per Share Basic | -0.01 | 0 | -0.02 |
| Earnings Per Share Diluted | -0.01 | 0 | -0.02 |
| Weighted Average Shares Outstanding Basic | 74,215,000 | 74,215,000 | 74,215 |
| Weighted Average Shares Outstanding Diluted | 74,215,000 | 74,215,000 | 74,215 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 46,859,000 | 47,012,000 | 46,982,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 293,000 | 331,000 | 405,000 |
| Total Assets Current | 47,152,000 | 47,343,000 | 47,387,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | — | — | — |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 17,000 | 359,000 | 202,000 |
| Total Assets | 47,169,000 | 47,702,000 | 47,589,000 |
| Accounts Payable | 331,000 | 331,000 | 331,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 72,000 | 108,000 | 93,000 |
| Total Liabilities Current | 1,678,000 | 1,714,000 | 1,699,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 0 | — | — |
| Total Liabilities Non Current | — | — | — |
| Total Liabilities | — | — | — |
| Common Stock | 742,000 | 742,000 | 742,000 |
| Retained Earnings | -69,892,000 | -70,670,000 | -72,043,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 3,008,000 | 3,505,000 | 3,407,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | — | — | — |
| Share Based Compensation Expense | — | — | — |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | — | — | — |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 1,122,000 | 1,305,000 | -659,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | — | — | — |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 0 | 0 | — |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 0 | 0 | 0 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -1,275,000 | -1,275,000 | — |
| Change In Cash | -153,000 | 30,000 | -659,000 |
| Cash At End Of Period | 46,859,000 | 47,012,000 | 46,982,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -0.01 | 0 | -0.02 |
| Price To Earnings Ratio | -15.61 | — | -12.335 |
| Earnings Growth Rate | — | -100 | -33.3333 |
| Price Earnings To Growth Ratio | — | — | 0.37 |
| Book Value Per Share | 0.613 | 0.6197 | 618.3386 |
| Price To Book Ratio | 0.2547 | 0.1509 | 0.0004 |
| Ebitda | — | — | — |
| Enterprise Value | — | — | — |
| Dividend Yield | 0 | 0 | 0 |
| Dividend Payout Ratio | 0 | 0 | 0 |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | — | — | — |
| Free Cash Flow | — | — | — |
| Return On Equity | 0.2586 | 0.3917 | -0.0546 |
| One Year Beta | 0.2528 | -0.2483 | 0.5445 |
| Three Year Beta | 0.3359 | 0.442 | 0.4446 |
| Five Year Beta | 0.3696 | 0.3454 | 0.339 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| READ RANDOLPH C | Director | 2023-06-16 | 84,550 | A | 200,000 |
| READ RANDOLPH C | Director | 2023-06-14 | 15,000 | A | 115,450 |
| COUCHMAN JONATHAN | 10% owner | 2021-08-13 | 50,000 | D | 350,000 |
| COUCHMAN JONATHAN | 10% owner | 2021-08-13 | 57,500 | D | 2,043,024 |
| READ RANDOLPH C | Director | 2020-11-18 | 50,000 | A | 100,450 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| PANAGORA ASSET MANAGEMENT INC | 2019-06-30 | 13,000 | 49,119 | 0.2647 |
| PANAGORA ASSET MANAGEMENT INC | 2019-03-31 | 11,000 | 49,119 | 0.2239 |
| PANAGORA ASSET MANAGEMENT INC | 2018-12-31 | 19,000 | 77,141 | 0.2463 |
| PANAGORA ASSET MANAGEMENT INC | 2018-09-30 | 16,000 | 64,923 | 0.2464 |
| WHITTIER TRUST CO | 2018-06-30 | 1,000 | 675 | 1.4815 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| USAA MUTUAL FUNDS TRUST | 2021-09-30 | Extended Market Index Fund | USMIX | 9,908 | 3,739.28 | 0.0004 |
| USAA MUTUAL FUNDS TRUST | 2021-06-30 | Extended Market Index Fund | USMIX | 10,408 | 6,869.28 | 0.0007 |
| USAA MUTUAL FUNDS TRUST | 2021-03-31 | Extended Market Index Fund | USMIX | 10,731 | 8,692.11 | 0.0009 |
| USAA MUTUAL FUNDS TRUST | 2020-12-31 | Extended Market Index Fund | USMIX | 11,065 | 2,748.49 | 0.0003 |
| USAA MUTUAL FUNDS TRUST | 2020-09-30 | Extended Market Index Fund | USMIX | 5,763 | 1,064.43 | 0.0001 |